ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 897,37
-0,12%
Dow Jones
44 858,89
0,32%
DAX
21 430,58
0,71%
Brent Oil
76,585
0,41%
Bitcoin
101 933,60
-0,13%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Humanigen Inc (HGEN)

  7. Humanigen Inc (HGEN) Actualités

HGEN

Humanigen (HGEN)

Humanigen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HGEN
DateHeureSourceTitreSymboleSociété
08/01/202423h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HGENHumanigen Inc
15/05/202312h36Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HGENHumanigen Inc
25/04/202322h06Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:HGENHumanigen Inc
19/04/202312h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HGENHumanigen Inc
01/02/202319h21Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:HGENHumanigen Inc
21/10/202211h45PR Newswire (US)HGEN SHAREHOLDER ALERT: Jakubowitz Law Reminds Humanigen Shareholders of a Lead Plaintiff Deadline of October 25, 2022NASDAQ:HGENHumanigen Inc
19/10/202211h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Humanigen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 25, 2022 - (NASDAQ: HGEN)NASDAQ:HGENHumanigen Inc
14/09/202212h15TipRanksH.C. Wainwright Remains a Hold on Humanigen (HGEN)NASDAQ:HGENHumanigen Inc
15/08/202212h16TipRanksHumanigen (HGEN) Gets a Hold from H.C. WainwrightNASDAQ:HGENHumanigen Inc
12/08/202222h00Business WireHumanigen Reports Second Quarter 2022 Financial ResultsNASDAQ:HGENHumanigen Inc
30/07/202200h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:HGENHumanigen Inc
13/07/202218h41TipRanksHumanigen Stock: Why It Crashed and Where It’s HeadedNASDAQ:HGENHumanigen Inc
13/07/202202h30Business WireHumanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-BNASDAQ:HGENHumanigen Inc
07/07/202205h34Business WireHumanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive ProteinNASDAQ:HGENHumanigen Inc
06/07/202200h57TipRanksHumanigen: Topline Data for Covid-19 Treatment Expected in July; What This Could Mean for the StockNASDAQ:HGENHumanigen Inc
01/07/202212h25TipRanksH.C. Wainwright Reiterates Their Buy Rating on Humanigen (HGEN)NASDAQ:HGENHumanigen Inc
30/06/202214h19Business WireNIH/NIAID Locks ACTIV-5/BET-B DatabaseNASDAQ:HGENHumanigen Inc
19/06/202209h20TipRanksH.C. Wainwright Thinks Humanigen’s Stock is Going to RecoverNASDAQ:HGENHumanigen Inc
17/06/202223h11Business WireHumanigen conclut un accord avec PCI Pharma Services dans le cadre des préparatifs de commercialisation au Royaume-UniNASDAQ:HGENHumanigen Inc
17/06/202223h09Business WireHumanigen trifft eine Vereinbarung mit PCI Pharma Services als Teil der Vorbereitungen für die Vermarktung im Vereinigten KönigreichNASDAQ:HGENHumanigen Inc
16/06/202212h30Business WireHumanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United KingdomNASDAQ:HGENHumanigen Inc
03/06/202213h00Business WireHumanigen Announces Participation and Presentation at Multiple Conferences in JuneNASDAQ:HGENHumanigen Inc
24/05/202212h30Business WireHumanigen Announces Participation and Presentation at H.C. Wainwright Global Investment ConferenceNASDAQ:HGENHumanigen Inc
12/05/202202h43TipRanksHumanigen: A ‘Transformative Year’ Awaits, Says AnalystNASDAQ:HGENHumanigen Inc
09/05/202221h25Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:HGENHumanigen Inc
05/05/202222h00Business WireHumanigen Reports First Quarter 2022 Financial ResultsNASDAQ:HGENHumanigen Inc
04/05/202213h00Business WireHumanigen Announces Participation and Presentation at Multiple Conferences in MayNASDAQ:HGENHumanigen Inc
20/04/202214h18Business WireHumanigen kündigt Veröffentlichung an, die von Experten begutachtet wurde und die potenziellen klinischen und wirtschaftlichen Vorteile von Lenzilumab aus Sicht des NHS darlegtNASDAQ:HGENHumanigen Inc
20/04/202200h53Business WireHumanigen annonce une publication évaluée par des pairs, qui démontre les avantages cliniques et économiques potentiels du lenzilumab du point de vue du NHSNASDAQ:HGENHumanigen Inc
19/04/202212h30Business WireHumanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHSNASDAQ:HGENHumanigen Inc
 Showing the most relevant articles for your search:NASDAQ:HGEN

Dernières Valeurs Consultées

EU
ORA
Orange
EU
PX1
CAC 40
COIN
ETHUSD
Ethereum
COIN
XRPUSD
Ripple
EU
EN
Bouygues
EU
VIV
Vivendi
SPI
SP500
S&P 500
NASDAQ
AAPL
Apple
EU
BNP
BNP Paribas
NYSE
NKE
Nike
NASDAQ
MSFT
Microsoft
EU
RNO
Renault
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés